Long-Acting HIV Treatment and Prevention: Closer to the Threshold

被引：25
|
作者：
Barnhart, Matthew [1 ]
机构：
[1] US Agcy Int Dev, Washington, DC 20523 USA
来源：
GLOBAL HEALTH-SCIENCE AND PRACTICE | 2017年 / 5卷 / 02期
关键词：
HUMAN-IMMUNODEFICIENCY-VIRUS; TENOFOVIR ALAFENAMIDE; PREEXPOSURE PROPHYLAXIS; IMPLANT; WOMEN; LEVONORGESTREL; INFECTION; COUNTRIES; DELIVERY; PRODRUG;
D O I：
10.9745/GHSP-D-17-00206
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
[No abstract available]
引用
收藏
页码：182 / 187
页数：6
相关论文
共 50 条
  • [21] Tenofovir alafenamide and elvitegravir loaded nanoparticles for long-acting prevention of HIV-1 vaginal transmission
    Mandal, Subhra
    Prathipati, Pavan K.
    Kang, Guobin
    Zhou, You
    Yuan, Zhe
    Fan, Wenjin
    Li, Qingsheng
    Destache, Christopher J.
    AIDS, 2017, 31 (04) : 469 - 476
  • [22] Patient preferences for long-acting HIV treatment: a preference heterogeneity assessment
    Saldarriaga, Enrique M.
    Hauber, Brett
    Barthold, Douglas
    Brah, Aaron T.
    Tran, Jacinda
    Marconi, Vincent C.
    Simoni, Jane M.
    Graham, Susan M.
    BMC INFECTIOUS DISEASES, 2025, 25 (01)
  • [23] The importance of the "how": the case for differentiated service delivery of long-acting and extended delivery regimens for HIV prevention and treatment
    Grimsrud, Anna
    Wilkinson, Lynne
    Delany-Moretlwe, Sinead
    Ehrenkranz, Peter
    Green, Kimberly
    Murenga, Maureen
    Ngure, Kenneth
    Otwoma, Nelson J.
    Phanuphak, Nittaya
    Vandevelde, Wim
    Vitoria, Marco
    Bygrave, Helen
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2023, 26
  • [24] An updated overview on long-acting therapeutics for the prevention and treatment of human immunodeficiency virus (HIV) from a perspective of pharmaceutics
    Dinh, Linh
    Blackard, Jason T.
    Robertson, Jaime
    Atreya, Abby
    Horner, Shaina
    Brown, Jennifer L.
    Gomez, Luis A.
    Beegle, Stephen
    Mahon, Lanesa
    Eades, William
    Abdolmohammadpourbonab, Shayan
    Liu, William
    Meeds, Heidi L.
    Fedders, Kevin
    Twitty, T. Dylanne
    Welge, Jeffrey A.
    Yan, Bingfang
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2025, 670
  • [25] Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV
    Bollinger, Robert C.
    Thio, Chloe L.
    Sulkowski, Mark S.
    McKenzie-White, Jane
    Thomas, David L.
    Flexner, Charles
    LANCET HIV, 2020, 7 (06): : E443 - E448
  • [26] Design strategies for long-acting anti-HIV pharmaceuticals
    Sang, Yali
    Ding, Li
    Zhuang, Chunlin
    Chen, Fener
    CURRENT OPINION IN PHARMACOLOGY, 2020, 54 : 158 - 165
  • [27] Topical delivery of long-acting antiretrovirals to prevent HIV acquisition
    Palanee-Phillips, Thesla
    Baeten, Jared M.
    CURRENT OPINION IN HIV AND AIDS, 2020, 15 (01) : 42 - 48
  • [28] Introduction: long-acting antiretrovirals for the treatment and prevention of HIV-1 infection: the future is now
    Markowitz, Martin
    CURRENT OPINION IN HIV AND AIDS, 2020, 15 (01) : 1 - 3
  • [29] Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research
    Cobb, Denise A.
    Smith, Nathan A.
    Edagwa, Benson J.
    McMillan, JoEllyn M.
    EXPERT OPINION ON DRUG DELIVERY, 2020, 17 (09) : 1227 - 1238
  • [30] Planning ahead for implementation of long-acting HIV prevention: challenges and opportunities
    Meyers, Kathrine
    Golub, Sarit A.
    CURRENT OPINION IN HIV AND AIDS, 2015, 10 (04) : 290 - 295
12345